Caris Life Sciences (Caris), the leading molecular science and technology company, and Xencor, Inc., a clinical-stage biopharmaceutical company, announced a multi-year strategic option and license agreement to research, develop and commercialize XmAb bispecific antibodies directed against novel targets for the treatment of patients with cancer.
Under the terms of the agreement, Caris will apply its proprietary end-to-end discovery platform, Caris Discovery, to identify novel targets for bispecific antibody drug candidates. Caris Discovery combines insights generated from molecular interrogation of primary patient tissues using ADAPT, the company
